– Collaboration will simplify providers' and
patients' access to discrete test results that can inform more
precise, personalized medicine –
SAN
FRANCISCO, March 21, 2023 /PRNewswire/
-- Invitae (NYSE: NVTA), a leading medical genetics
company, today announced its partnership with Epic, an
industry-leading healthcare software company.
Through Aura, Epic's specialty diagnostics suite, Invitae will
streamline interactions with provider organizations in the Epic
community, making test result information available in providers'
usual workflows so that it's easier to use genetic insights to
inform treatment decisions.
"Genetic testing can inform some of the most important care
decisions in patients' lives, and Invitae is making it more
accessible to both patients and providers across the Epic
community," said Dave Fuhrmann,
senior vice president of research and development at Epic. "Aura
will help them do so by further enabling precision medicine at many
of the nation's leading healthcare organizations."
"Our use of Aura allows patients and providers to seamlessly
access genetic testing that can help identify at-risk individuals,
enhance early detection and better personalize treatments with the
goals of achieving better outcomes and reducing the burden on the
broader healthcare system," said Robert
Nussbaum, M.D., chief medical officer at Invitae.
For more information, visit Invitae.com.
About Invitae
Invitae (NYSE: NVTA) is a leading medical genetics company trusted
by millions of patients and their providers to deliver timely
genetic information using digital technology. We aim to provide
accurate and actionable answers to strengthen medical
decision-making for individuals and their families. Invitae's
genetics experts apply a rigorous approach to data and research,
serving as the foundation of their mission to bring comprehensive
genetic information into mainstream medicine to improve healthcare
for billions of people.
To learn more, visit invitae.com and follow for updates on
Twitter, Instagram, Facebook and LinkedIn @Invitae.
Safe Harbor Statement
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
relating to the company's beliefs regarding its collaboration with
Epic, including that the partnership will simplify providers' and
patients' access to discrete test results that can inform more
precise, personalized medicine. Forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially, and reported results should not be considered
as an indication of future performance. These risks and
uncertainties include, but are not limited to: the impact of
inflation and the current economic environment on the company's
business; the company's ability to grow its business in a
cost-efficient manner; the company's history of losses; the
company's ability to maintain important customer
relationships; the company's ability to compete; the company's
need to scale its infrastructure in advance of demand for its tests
and to increase demand for its tests; the applicability of clinical
results to actual outcomes; risks associated with litigation; the
company's ability to use rapidly changing genetic data to interpret
test results accurately and consistently; security breaches, loss
of data and other disruptions; laws and regulations applicable to
the company's business; and the other risks set forth in the
company's filings with the Securities and Exchange Commission,
including the risks set forth in the company's Annual Report on
Form 10-K for the year ended December 31,
2022. These forward-looking statements speak only as of the
date hereof, and Invitae Corporation disclaims any obligation to
update these forward-looking statements.
Invitae PR contact:
Renee Kelley
pr@invitae.com
(628) 213-3283
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invitae-announces-partnership-with-epic-to-streamline-genetic-testing-301776648.html
SOURCE Invitae Corporation